BiomX Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $6.037 million, compared to a net income of $4.471 million in the same period of the previous year. The company’s revenue for the quarter was not specified, but it noted a significant operating loss of $7.433 million, down from $9.725 million in the prior year. For the first half of 2025, the net loss totaled $13.696 million, slightly higher than the $12.856 million loss reported for the same period in 2024. The basic loss per share for the second quarter was $0.19, compared to earnings of $0.14 per share in the previous year.
In terms of operational changes, BiomX's total current assets decreased to $16.635 million as of June 30, 2025, from $20.520 million at the end of 2024. The company’s cash and cash equivalents also fell to $14.046 million from $16.856 million during the same period. The decline in cash reserves is attributed to ongoing operational expenses and the need for additional funding to support research and development activities. The company has indicated that it plans to continue funding its operations through the issuance of debt and equity securities, loans, and government grants.
BiomX has been actively pursuing strategic developments, including the acquisition of Adaptive Phage Therapeutics (APT) in March 2024, which has expanded its pipeline to include two Phase 2 assets aimed at treating serious bacterial infections. The merger has been a significant focus for the company, and it has incurred transaction costs related to this acquisition. The company’s employee headcount remains stable, although specific figures were not disclosed in the filing.
The company continues to face challenges related to geopolitical instability in Israel, where its headquarters are located. Despite the ongoing conflict, BiomX has reported that its operations have not been materially impacted, and it does not anticipate delays in its programs. However, the company acknowledges that the situation remains volatile and could affect its business in the future. Looking ahead, BiomX has expressed concerns about its ability to continue as a going concern, given its accumulated deficit of $194.393 million as of June 30, 2025, and the need for additional funding to sustain its operations and development activities.
About BiomX Inc.
BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies that target harmful bacteria linked to chronic diseases like cystic fibrosis and diabetic foot osteomyelitis. Utilizing proprietary platforms—BOLT for engineered phage cocktails and PST for personalized phage matching—BiomX designs natural and synthetic bacteriophage treatments. Its business model focuses on precise bacterial targeting to address antibiotic resistance, serving patients through clinical development and potential future commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov